Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory carcinosarcoma
(mixed mesodermal tumors) of the uterus Measurable disease

PATIENT CHARACTERISTICS: Age: Not specified Performance Status: GOG 0-2 Life Expectancy:
Not specified Hematopoietic: Platelet count at least 100,000/mm3 Absolute granulocyte
count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of
normal (ULN) SGOT no greater than 3 times ULN Alkaline phosphatase no greater than 3 times
ULN Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance greater than 20
mL/min Other: No invasive malignancies within the past 5 years except nonmelanomatous skin
cancer No significant infection

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy
Chemotherapy: At least 3 weeks since prior chemotherapy and recovered No prior topotecan
or camptothecin therapy No more than 1 prior chemotherapy regimen (either single or
combination chemotherapy) Endocrine therapy: At least 3 weeks since prior endocrine
therapy Radiotherapy: At least 3 weeks since prior radiotherapy and recovered Surgery:
Prior surgery allowed and recovered